Showing 6581-6590 of 6786 results for "".
- Suneva Medical Completes Initial Treatment in Phase 3 Acne Scar Studyhttps://practicaldermatology.com/news/20121024-suneva_medical_completes_initial_treatment_in_phase_3_acne_scar_study/2459695/Suneva Medical, Inc. announced that it has completed the enrollment and initial treatment of patients in its Phase 3 acne scar study. This multi-center, prospective study is investigating the efficacy of Artefill for the treatment of moderate to
- AES 2012 Registration Closedhttps://practicaldermatology.com/news/20121022-aes_2012_registration_closed/2459697/Aesthetic Extender Symposium 2012 has reached maximum capacity and will be held the first week in November. The event next year will be from September 26 to 29, 2013. Updates are available here.
- MBA Aesthetics Course Finalizes Facultyhttps://practicaldermatology.com/news/20121017-mba_aesthetics_course_finalizes_faculty/2459703/“Mastering the Business of Aesthetics,” a one-day course taking place on October 27, will offer attendees insight on various clinical and financial elements of aesthetics practice. The faculty includes Paul S. Nassif, MD, FACS, Melanie Palm, MD, MBA, Nissan Pilest, MD, Robert James Troell, MD, FASC,
- ASDS: Study Shows that PCPs Favor Dermatologists for Cosmetic Procedureshttps://practicaldermatology.com/news/20121016-new_study_from_asds_shows_that_pcps_favor_dermatologists_for_cosmetic_procedures/2459705/Recent survey data presented at the recent ASDS Meeting in Atlanta and published in the October edition of Dermatologic Surgery finds that almost two-thirds of physicians chose dermatologists as the most qualified to perform cosmetic procedures for wrinkles and skin rejuvenation. Additionally, resul
- Restoration Robotics, Inc. Appoints Cary Rayment to Board of Directorshttps://practicaldermatology.com/news/20121015-restoration_robotics_inc_appoints_cary_rayment_to_board_of_directors/2459706/Cary Rayment joined the Board of Directors of Restoration Robotics, Inc.. He previously served as President and Chief Executive Officer of Alcon, Inc. until 2009 and then as non-executive chairman and director of Alcon, Inc.
- Actress Cynthia Nixon Helps Americans to Come Face to Face with Rosaceahttps://practicaldermatology.com/news/20121014-actress_cynthia_nixon_wants_americans_to_come_face_to_face_with_rosacea/2459707/Some of the 16 million Americans affected by rosacea are not seeking therapy, but a new initiative encourages them to come "Face to Face" with the disease. Supported by Galderma in association with the National Rosacea Society
- Acanya Announces College Scholarship Programhttps://practicaldermatology.com/news/20121010-acanya_announces_college_scholarship_program/2459711/Sponsored by Valeant Dermatology, the I Acanya Succeed Scholarship program was created to help students who have had acne and have actively tried to address it. The scholarship will award a total of up to $48,000 each to three US citize
- Strathspey Crown Hosts Founders Summithttps://practicaldermatology.com/news/20121002-strathspey_crown_hosts_founders_summit/2459717/Strathspey Crown recently hosted its Founders Summit & Retreat at Pelican Hill in Newport Beach, CA. The event gathered approximately 50 of the top physicians from elective healthcare and national leaders from government, healthcare, and f
- Stiefel/GSK Receives FDA Approval of Sorilux Foam, 0.005%https://practicaldermatology.com/news/20121002-stiefel_receives_fda_approval_of_sorilux_foam_0005/2459719/The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005% from Stiefel/GSK. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psor
- Janssen to Develop, Commercialize JAK Inhibitor For Immunological Diseaseshttps://practicaldermatology.com/news/20121002-janssen_to_develop_commercialize_jak_inhibitor_for_immunological_diseases/2459720/Janssen Biotech, Inc. entered into a license agreement with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for mod